MSD Korea has announced that it will discontinue the domestic supply of the shingles vaccine Zostavax in Korea.

According to the Ministry of Food and Drug Safety, MSD reported the suspension of Zostavax to the Ministry of Food and Drug Safety on Monday. The last batch is expected to be delivered within September, but the supply period is subject to change depending on market demand.

Zostavax is a shingles vaccine that was launched in 2013. It was the first live attenuated vaccine available in South Korea.

According to the market research institution IQIVA, Zostavax generated KRW 22.4 billion in sales last year, which is half the KRW 55.9 billion it had posted in 2019.